Pyranoside derivatives

Details Pyranoside derivatives Pyranoside derivatives

1999-03-08

2001-03-06

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S532000, C514S546000

Reexamination Certificate

active

06197753

ABSTRACT:

DESCRIPTION OF THE INVENTION
The present invention relates to new pyranoside derivatives, processes for preparing them and their use in pharmaceutical compositions. The new pyranoside derivatives correspond to general formula I
wherein
1, m and n independently of one another denote an integer chosen from 0, 1, 2, 3 and 4 and 1+m+n<4
in the form of their racemates, in enantiomerically pure or concentrated form, optionally as pairs of diastereomers and are obtained in the form of free bases or salts, preferably with physiologically acceptable acids.
The compounds according to the invention are potent LTB
4
-antagonists. In particular the compound of Example 1 is obtained in vivo as a metabolite of an LTB
4
-antagonistic compound and in the receptor binding test it has a K
i
-value of 1.0 nM.
As has been found, the compounds of formula I are characterised by their versatility of use in the therapeutic field. Particular mention should be made of those applications in which the LTB
4
-receptor-antagonistic properties play a part. Examples include, in particular: arthritis, asthma, chronic obstructive lung diseases, such as chronic bronchitis, psoriasis, ulcerative colitis, gastropathy or enteropathy induced by nonsteroidal antiinflammatories, cystic fibrosis, Alzheimer's disease, shock, reperfusion damage/ischaemia, atherosclerosis and multiple sclerosis.
The new compounds may also be used to treat diseases or conditions in which the passage of cells from the blood through the vascular endothelium into the tissues is of importance (such as metastasis) or diseases and conditions in which the combination of LTB
4
or another molecule (such as 12-HETE) with the LTB
4
-receptor influences cell proliferation (such as chronic myeloid leukaemia).
The new compounds may also be used in combination with other active substances, e.g. those which are used for the same indications, or for example with antiallergics, secretolytics, 12-adrenergics, inhaled steroids, antihistamines and/or PAF-antagonists. They may be administered by topical, oral, transdermal, nasal or parenteral route or by inhalation.
The activity ratios may be investigated pharmacologically and biochemically using tests such as those described in WO 93/16036, pp. 15 to 17 —the contents of which are referred to herein.
The therapeutic or prophylactic dose depends not only on the potency of the individual compounds and the body weight of the patient but also on the nature and gravity of the illness. For oral administration the dose is between 10 and 500 mg, preferably between 20 and 250 mg. For inhalation the patient is given between about 0,5 and 25 mg, preferably between about 2 and 20 mg of active substance.
Inhalable solutions generally contain between about 0.5 and 5% of active substance. The new compounds may be administered in conventional preparations, e.g. as plain or coated tablets, capsules, lozenges, powders, granules, solutions, emulsions, syrups, inhalable aerosols, ointments or suppositories.
The Examples which follow show some possible ways of formulating the preparations:
Formulation examples
1. Tablets
Composition:
Active substance according to invention
 20 parts by weight
Stearic acid
 6 parts by weight
Glucose
474 parts by weight
The ingredients are processed in the usual way to form tablets weighing 500 mg. If desired the content of active substance may be increased or reduced and the quantity of glucose reduced or increased accordingly.
2. Suppositories
Composition:
Active substance according to invention
 100 parts by weight
Lactose, powdered
 45 parts by weight
Cocoa butter
1555 parts by weight
The ingredients are processed in the usual way to form suppositories weighing 1.7 g.
3. Powder for Inhalation
Micronised active substance powder (compound of formula I; particle size about 0.5 to 7 &mgr;m) is packed into hard gelatin capsules in a quantity of 5 mg, optionally with the addition of micronised lactose. The powder is inhaled from conventional inhalers, e.g. according to DE-A 33 45 722, which is referred to herein.
The compounds according to the invention are prepared by methods which are known per se from the prior art. Thus, the compounds of general formula I
wherein 1, m and n are as hereinbefore defined, are prepared by reacting 4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]-benzenecarboximidamide with a glucose derivative of general formula II
wherein when n>0 the carboxyl group is optionally protected in the form of a C
1
-
4
-alkyl ester and the hydroxy groups are protected in the form of acyl groups of an aliphatic or aromatic carboxylic acid and X denotes a leaving group which may be displaced by a phenoxide oxygen, converted from a phenoxide and optionally the ester groups are saponified.
The compounds according to the invention may also be prepared from an optionally protected glucose derivative (II) and the abovementioned phenol using basic heavy metal compounds such as Ag
2
O or CdCO
3
in inert solvents such as toluene or dichloromethane. The product is optionally freed of the protecting groups by saponification.
The compounds (I) may also be prepared from derivatives of formula (II) and the abovementioned phenol using Lcwis acids such as, for example, BF
3
, AlCl
3
, ZnCl
2
, SnCl
4
, TiCl
4
, or from alkoxide derivatives of these Lewis acids in inert solvents such as toluene, dichloromethane, etc.
Furthermore, the compounds according to the invention may be prepared from an optionally protected derivative (II) wherein X═OH and the abovementioned phenol using acid catalysts such as e.g. methanesulphonic acid or tetrafluoroboric acid or using Lewis acids such as for example BF
3
, AlCl
3
, ZnCl
2
, SnCl
4
, TiCl
4
, or from alkoxide derivatives of these Lewis acids in inert solvents such as aliphatic, aromatic, alkylsubstituted aromatics or in a halogenated hydrocarbon—preferably in toluene or in dichloromethane.
C
1
-
4
-alkyl in the preparation processes described above generally represents a branched or unbranched hydrocarbon group having 1 to 4 carbon atoms, which may optionally be substituted with one or more halogen atoms—preferably fluorine—, which may be identical to or different from one another. Examples include the following hydrocarbon groups: methyl, ethyl, propyl, 1-methylethyl (isopropyl), n-butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl.
The compounds according to the invention may be prepared starting from compounds which are known from the prior art, using inter alia the methods described in the following Examples. Various other embodiments of the processes will become apparent to the skilled person from the description provided. However, it is expressly pointed out that these Examples and the associated description are provided solely for illustration and must not be regarded as limiting the invention.


REFERENCES:
patent: 5246965 (1993-09-01), Main
F.C. Barone et al., Time-Related Changes in Myeloperoxidas Activity and Leukotriene B4 Receptor Binding Reflect Leukocyte Influx in Cerebral Focal Stroke, Mol. Chem. Neuropathology 1995, 24:13-30 [Barone et al.].
J. Britton, Dietary Fish Oil and Airways Obstruction, Thorax 1995, 50 (Suppl. 1): 511-515 [Britton].
U. Costabel et al., Local Immune Components in Chronic Obstructive Pulmonary Disease, Respiration 1992, 59(Suppl. 1): 17-19 [Costabel et al.].
K. Schlosser et al., Increased Leukotriene B4 Snythesis in Polymorphonuclear Leukocytes of Smokers, Klin Wochenschr 1988, 66 (Suppl. XI): 120-124 [Schlosser et al.].
W.H. Thornton, Jr. et al., Leukotriene B4 is Measurable in Serum of Smokers and Nonsmokers, Clin. Chem. 1989, 35/3: 459-460 [Thornton et al.].
A.B. Thompson, Intraluminal Airway Inflammation in Chronic Bronchitis, Am. Rev. Respir. Dis. 1989, 140:1527-1537 [Thompson et al.].
D. Stanescu et al., Airway Obstruction, Chronic Expectoration, and Rapid Decline of FEV1 in Smokers are Associated with Increased Levels of Sput

Affiliated with

Also associated with

Rating

Pyranoside derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyranoside derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyranoside derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2479932